Clinical trial
A Phase IV Observational Study Evaluating the Efficacy and Safety of Anlotinib in Combination With Penpulimab as First-line Treatment in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05319886 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xinxiang Medical College as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IV Observational Study Evaluating the Efficacy and Safety of Anlotinib in Combination With Penpulimab as First-line Treatment in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- The First Affiliated Hospital of Xinxiang Medical College
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- May 16, 2022
- Completion date
- March 30, 2025
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
lung cancer, lung carcinoma, lung neoplasm, non small cell lung cancer, non-small cell carcinoma